UBS Bets on Viking’s VK2735 to Stand Out in Crowded Obesity Market with $94 Target VK2735 shows rapid weight loss in Phase 2, with financing through 2027. Credit: Viking Therapeutics Subscribe now Already have an account? Sign in.
